Weave Bio, a software platform that automates regulatory paperwork for drug development, raised a $20 million Series A, CEO Brandon Rice tells Axios Pro exclusively.
Why it matters: The software startup operates in a booming space for AI-powered drug development tools — but claims its early entry gives it an edge.
